July 5, 2023 06:51 AM EDT
Bioregnum

The H1 pic­ture: Biotech’s vi­tal signs show some life — with one big ex­cep­tion

This past six months, the num­bers have start­ed to track up­ward in biotech — and we’re not just talk­ing about M&A here.

We’re start­ing to see …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Seres' mi­cro­bio­me ther­a­py re­duces in­fec­tions in stem cell trans­plant pa­tients, but next steps are un­clear

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

FDA should em­brace new ways of eval­u­at­ing rare dis­ease drugs, re­port ar­gues

A service from the Financial Times